J Acquir Immune Defic Syndr. 2007 May 1;45(1):20-7.

Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay.

Dubey S, Clair J, Fu TM, Guan L, Long R, Mogg R, Anderson K, Collins KB, Gaunt C, Fernandez VR, Zhu L, Kierstead L, Thaler S, Gupta SB, Straus W, Mehrotra D, Tobery TW, Casimiro DR, Shiver JW.

Source

Department of Vaccine and Biologics Research, Merck Research Laboratories, West Point, PA 19486, USA. sheri_dubey@merck.com

Abstract

An effective vaccine for HIV is likely to require induction of T-cell-mediated immune responses, and the interferon-gamma (IFNgamma) enzyme-linked immunospot (ELISPOT) assay has become the most commonly used assay for measuring these responses in vaccine trials. We optimized and validated the HIV ELISPOT assay using an empirical method to establish positivity criteria that results in a < or =1% false-positive rate. Using this assay, we detected a broad range of HIV-specific ELISPOT responses to peptide pools of overlapping 20mers, 15mers, or 9mers in study volunteers receiving DNA- or adenovirus vector-based HIV vaccines and in HIV-seropositive donors. We found that 15mers generally had higher response magnitudes than 20mers and lower false-positive rates than 9mers. These studies show that our validated ELISPOT assay using 15mer peptide pools and the positivity criteria of > or =55 spots per 10(6) cells and > or =4-fold over mock (negative control) is a sensitive and specific assay for the detection of HIV vaccine-induced cell-mediated immunity.

PMID:: 17310936; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Education

New England Research Institutes Inc.

Supplemental Content

Related citations

Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines. [AIDS Res Hum Retroviruses. 2002]
Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines.
Mwau M, McMichael AJ, Hanke T. AIDS Res Hum Retroviruses. 2002 Jun 10; 18(9):611-8.
Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC. [AIDS Res Hum Retroviruses. 2007]
Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC.
Kierstead LS, Dubey S, Meyer B, Tobery TW, Mogg R, Fernandez VR, Long R, Guan L, Gaunt C, Collins K, et al. AIDS Res Hum Retroviruses. 2007 Jan; 23(1):86-92.
Cross-clade T lymphocyte-mediated immunity to HIV type 1: implications for vaccine design and immunodetection assays. [AIDS Res Hum Retroviruses. 2002]
Cross-clade T lymphocyte-mediated immunity to HIV type 1: implications for vaccine design and immunodetection assays.
Keating SM, Bollinger RC, Quinn TC, Jackson JB, Carruth LM. AIDS Res Hum Retroviruses. 2002 Sep 20; 18(14):1067-79.
Review The ELISPOT assay: an easily transferable method for measuring cellular responses and identifying T cell epitopes. [Clin Chem Lab Med. 2002]
Review The ELISPOT assay: an easily transferable method for measuring cellular responses and identifying T cell epitopes.
Mashishi T, Gray CM. Clin Chem Lab Med. 2002 Sep; 40(9):903-10.
Review Quantification and characterization of specific T-cells by antigen-specific cytokine production using ELISPOT assay or intracellular cytokine staining. [Methods. 2003]
Review Quantification and characterization of specific T-cells by antigen-specific cytokine production using ELISPOT assay or intracellular cytokine staining.
Letsch A, Scheibenbogen C. Methods. 2003 Oct; 31(2):143-9.

See reviews... See all...

Cited by 22 PubMed Central articles

CTL Responses of High Functional Avidity and Broad Variant Cross-Reactivity Are Associated with HIV Control. [PLoS One. 2012]
CTL Responses of High Functional Avidity and Broad Variant Cross-Reactivity Are Associated with HIV Control.
Mothe B, Llano A, Ibarrondo J, Zamarreño J, Schiaulini M, Miranda C, Ruiz-Riol M, Berger CT, Herrero MJ, Palou E, et al. PLoS One. 2012; 7(1):e29717. Epub 2012 Jan 4.
Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial. [PLoS One. 2011]
Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial.
Koblin BA, Casapia M, Morgan C, Qin L, Wang ZM, Defawe OD, Baden L, Goepfert P, Tomaras GD, Montefiori DC, et al. PLoS One. 2011; 6(9):e24517. Epub 2011 Sep 12.
Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study. [PLoS One. 2011]
Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study.
Li F, Finnefrock AC, Dubey SA, Korber BT, Szinger J, Cole S, McElrath MJ, Shiver JW, Casimiro DR, Corey L, et al. PLoS One. 2011; 6(6):e20479. Epub 2011 Jun 10.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clin...
Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay.
J Acquir Immune Defic Syndr. 2007 May 1 ;45(1):20-7.

PubMed
Personality constructs and perceived presence of deceased loved ones.
Personality constructs and perceived presence of deceased loved ones.
Death Stud. 1997 Mar-Apr ;21(2):131-46.

PubMed
Causes of telengiectasias, reticular veins, and varicose veins.
Causes of telengiectasias, reticular veins, and varicose veins.
Semin Vasc Surg. 2005 Mar ;18(1):2-4.

PubMed
The 2004 WHO classification of bladder tumors: a summary and commentary.
The 2004 WHO classification of bladder tumors: a summary and commentary.
Int J Surg Pathol. 2005 Apr ;13(2):143-53.

PubMed
Columbin inhibits cholesterol uptake in bloodstream forms of Trypanosoma brucei-...
Columbin inhibits cholesterol uptake in bloodstream forms of Trypanosoma brucei-A possible trypanocidal mechanism.
J Enzyme Inhib Med Chem. 2005 Aug ;20(4):365-8.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Education

Supplemental Content

Related citations

Cited by 22 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information